Bcl6 clone p1f6

Formalin-fixed paraffin-embedded tissues were stained with hematoxylin and eosin at the initial diagnosis. Immunohistochemistry was performed using the following panel of monoclonal and polyclonal antibodies: CD20 (clone L26, DAKO, Glostrup, Denmark); CD79a (clone 1.10E + 04, Leica Biosystems, Wetzlar, Germany); PAX5 (clone R1, DAKO); CD10 (clone 56C6, Leica Biosystems); BCL6 (clone P1F6, DAKO); MUM1 (clone MUM1p, DAKO); Ki-67 (clone MIB-1, DAKO); Terminal deoxynucleotidyl transferase (TDT, clone SP150, DAKO); CD2 (clone AB75, DAKO); CD3 (clone LN10, Leica Biosystems); CD4 (clone SP35, DAKO); CD7 (DAKO); CD8 (clone SP16, DAKO); CD1a (clone SP157, DAKO); CD34 (clone QBEnd/10, DAKO); CD43 (clone DF-T1, DAKO); CD99 (clone HO36-1.1, DAKO); CD117 (clone C-KIT, DAKO); CD45 (clone PAN-LCAL, DAKO); CD33 (clone WM-54, DAKO); MPO (clone SP72, DAKO); CD15 (clone C3D-1, DAKO); CD30 (clone Ber-H2, DAKO); CD23 (clone SP23, DAKO); and Epithelial membrane antigen (EMA, clone GP1.4, Leica Biosystems).

Formalin-fixed, paraffin-embedded tissue samples were available for all the 36 cases and were stained with hematoxylin and eosin (HE) at initial diagnosis. Immunohistochemistry was performed using a panel of monoclonal and polyclonal antibodies, as follows: CD20 (clone L26, DAKO, Glostrup, Denmark); CD79a (clone 1.10E+04, Leica Biosystems, Wetzlar, Germany); PAX5 (clone R1, DAKO); CD10 (clone 56C6, Leica Biosystems); BCL6 (clone P1F6, DAKO); MUM1 (clone MUM1p, DAKO); Ki-67 (clone MIB-1, DAKO); BCL2 (clone 100/D5, DAKO); MYC (DAKO); EBV (DAKO); terminal deoxynucleotidyl transferase (TDT, clone SP150, DAKO); CD3 (clone LN10, Leica Biosystems); CD43 (clone DF-T1, DAKO). MYC was considered as positive when > 40% of tumor cells exhibited staining [20 ]. Positivity threshold was defined at 50% for BCL2 [20 ], and at 30% for CD10, BCL6, and MUM1 [4 (link)]. For sub-classification of DLBCLs, GC immunophenotype was evaluated by antibodies of C10, BCL6 and MUM1 [4 (link)].